Life Science Virtual Investor Forum Agenda Announced for September 18th

Life Science Virtual Investor Forum Agenda Announced for September 18th

Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR.

Individual investors, institutional investors, advisors, and analysts are invited to attend.

REGISTER HERE

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management.

Please schedule 1x1 meetings here

"We are excited to highlight today's innovators from the life science sector ," said Jason Paltrowitz, Executive Vice President of Corporate Services at OTC Markets Group. "Our Virtual Investor Conferences empower investors to connect and understand the vision driving these companies firsthand."

September 18 th

Eastern
Time (ET)
Presentation Ticker(s)
9:30 AM ET Amplia Therapeutics Limited (Pink: INNMF | ASX: ATX)
10:00 AM ET Kelyniam Global, Inc. (OTCID: KLYG)
10:30 AM ET United Health Products, Inc. (OTCQB: UEEC)
11:00 AM ET PetVivo Holdings, Inc. (OTCQX: PETV)
11:30 AM ET Dermata Therapeutics, Inc. (NASDAQ: DRMA)
12:00 PM ET Hemostemix Inc. (OTCQB: HMTXF | TSXV: HEM)
12:30 PM ET Lipella Pharmaceuticals Inc. (OTCID: LIPO)
2:00 PM ET InMed Pharmaceuticals Inc. (NASDAQ: INM)
2:30 PM ET Accustem Sciences Inc. (OTCQB: ACUT)
3:00 PM ET Sigyn Therapeutics Inc. (OTCQB: SIGY)
4:00 PM ET Percheron Therapeutics Ltd. (OTCID: PERCF | ASX: PER)


To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com .

About Virtual Investor Conferences ®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

Media Contact:
OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

Virtual Investor Conferences Contact:
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

INM
The Conversation (0)
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth... Keep Reading...
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small... Keep Reading...
InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright... Keep Reading...
InMed to Present INM-901 Data at Alzheimer's Association International Conference  2025

InMed to Present INM-901 Data at Alzheimer's Association International Conference 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activityInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases... Keep Reading...
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement... Keep Reading...

Latest Press Releases

Related News